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Reactive free oxygen radicals are known to play an important role in the pathogenesis of various lung diseases such 
as idiopathic pulmonary fibrosis (IPF); adult respiratory distress syndrome (ARDS) or cystic fibrosis (CF). They can 
originate from endogenous processes or can be part of exogenous exposures (e.g. ozone, cigarette smoke, asbestos 
fibres). Consequently, therapeutic enhancement of anti-oxidant defence mechanisms in these lung disorders seems a 
rational approach. In this regard, N-acetyl-L-cysteine (NAC) and ambroxol have both been frequently investigated. 
Because of its SH group; NAC scavenges H,O, (hydrogen peroxide), -OH (hydroxol radical), and HOC1 
(hypochlorous acid). Furthermore, NAC can easily be deacetylated to cysteine, an important precursor of cellular 
glutathione synthesis, and thus stimulate the cellular glutathione system. This is most evident in pulmonary diseases 
characterized by low glutathione levels and high oxidant production by inflammatory cells (e.g. in IPF and ARDS). 
NAC is an effective drug in the treatment of paracetamol intoxication and may even be protective against side-effects 
of mutagenic agents. In addition NAC reduces cellular production of pro-inflammatory mediators (e.g. TNF-a, 
IL-l). 
Also, ambroxol [tvans-4-(2-amino-3,5-dibromobenzylamino)-cyclohexane hydrochloride] scavenges oxidants (e.g. 
*OH, HOCl). Moreover, ambroxol reduces bronchial hyperreactivity, and it is known to stimulate cellular surfactant 
production. In addition, ambroxol has anti-inflammatory properties owing to its inhibitory effect on the production 
of cellular cytokines and arachidonic acid metabolites. For both substances effective anti-oxidant and anti- 
inflammatory function has been validated when used in micromolar concentrations. These levels are attainable 
in viva in humans. This paper gives an up-to-date overview about the current knowledge of the hypothesis that 
oxidant-induced cellular damage underlies the pathogenesis of many human pulmonary diseases, and it discusses the 
feasibility of anti-oxidant augmentation therapy to the lung by using NAC or ambroxol. 
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Introduction 
Reactive oxygen species (ROS) are constantly formed in the 
lung and serve a physiological role. Once radicals are 
formed they can (a) destroy micro-organisms, normal 
or neoplastic mammalian cells and (b) modulate the 
inflammatory response (e.g. mediator release of inflam- 
matory cells). However, when generated in excess, or in 
inappropriate environments, and when anti-oxidant 
defence is insufficient, radicals can damage DNA, lipids, 
proteins and carbohydrates [for review see l-31. In the lung 
in particular, various diseases are known where oxygen 
metabolites play a predominant role in the pathogenesis 
(Table 1). 
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Based on this knowledge, anti-oxidant augmentation 
therapy seems to be a rational approach in pulmonary 
diseases characterized by an overload of radicals or lack of 
anti-oxidants. In this regard, N-acetyl-L-cysteine (NAG) 
and ambroxol, both widely used in Europe as mucolytic 
agents, have been investigated thoroughly in the recent 
past. The purpose of this article is to summarize these 
findings in order to assess clinical feasibility of anti-oxidant 
therapy with these drugs. 
The Role of Oxidants in Living Systems 
FREE RADICALS 
A free radical is any species capable of independent exis- 
tence that contains one or more unpaired electrons, where 
an unpaired electron is one that occupies an atomic or 
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TABLE 1. Reactive oxygen intermediates are regarded to play a considerable role (a) in the pathogenesis of various pulmonary 
inflammatory disorders and (b) after inhalation of various substances [summarized from (59,155-1581 
Disease or exposure Source of oxidant 
Adult respiratory distress syndrome (ARDS) 
Cystic fibrosis 
Idiopathic pulmonary fibrosis (IPF) 
Asthma 
Hyperoxia 
Ozone 
Asbestosis 
Silicosis 
Paraquat toxicity 
Bleomycin toxicity 
Cigarette smoking 
Ionizing radiation 
HIV infection 
Stimulated PMN cells 
Stimulated PMN cells, lack of fat-soluble anti-oxidants 
(caused by exocrine pancreatic insufficiency) 
Stimulated PMN cells, and alveolar macrophages, pulmonary GSH 
deficiency 
Stimulated PMN cells and eosinophils 
0, - formation from transport chains 
0,: formation of 0, -, *OH and H,O,, release of cycle-oxygenase metabo- 
lites of arachidonic acid 
Fe*+, stimulated macrophages 
Fe2+ after formation of silicato-iron complexes 
Redox cycling 
Formation of 0, - and *OH from Fe2’-bleomycin complex 
H,O,, NO, peroxyl compounds, quinones, stimulated PMN cells and 
macrophages 
0, - formation by ionization 
Systemic deficiency of acid-soluble thiols 
TABLE 2. Examples of oxygen species [the terms oxidants and ROS includes oxygen radicals and other derivates of 0, 
(non-radicals) (4)] 
Formula Description Comments 
Radicals 
02- 
*OH 
RO,, RO’ 
NO., NO, 
Non-radicals 
H202 
HOC1 
03 
Superoxide anion Produced by a number of enzymes, auto-oxidation reactions and non-enzymatic 
electron transfers. 
Conversion to H202 [by superoxide dismutase (SOD) and 0,] or *OH (Fenton 
reaction). 
Hydroxy radical Highly reactive 
Peroxyl, alkoxyl radicals Occur as organic radicals during the breakdown of peroxides of lipids (peroxida- 
tion) 
Oxides of nitrogen Nitric oxide and nitrogen dioxide can be found in viva (NO’) and in polluted air 
(NO,). 
Hydrogen peroxide 
Hypochlorous acid 
Ozone 
H,O, occurs from 0, - by many enzymatic reactions. 
From H,O, *OH can be formed. 
It is formed by action of myeloperoxidase in inflammatory reactions 
Formed in the environment. 
molecular orbital by itself (4). ROS is a collective term that 
includes not only free oxygen radicals but also some 
derivatives of 0, that do not contain unpaired electrons 
such as H,O, (hydrogen peroxide), ‘02 (singlet oxygen), 0, 
(ozone) and HOC1 (hypochlorous acid) (Table 2). The 
reactivity of the most frequently occurring ROS is as 
follows (5): 
O,<O, ~ <H,O,c*OH 
Oxidants are generated by various chemical processes (e.g. 
certain drugs, metals) and enzymatic reactions, or they can 
directly be inhaled (e.g. smoking, ozone, hyperoxia) [for 
review see (6-g)]. 
Myeloperoxidase, present in polymorphonuclear (PMN) 
cells and released during respiratory burst, converts 
H,O, into HOCl, another highly toxic oxidant which can 
further react to form more long-lived chloramines (9). 
Triggered by SOD, O,- (superoxide anion) quickly 
dismutates to H,O, from which highly reactive *OH 
(hydroxyl radical) can be formed in the presence of 
transition metals such as iron. Iron- (or copper-) catalysed 
reactions are often referred to as either the Haber-Weiss 
reaction (formation of -OH from H,O, and O,-) or 
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the Fenton reaction (formation of *OH from H,O,) 
(10,ll). Since H,O, easily diffuses through cell membranes 
.OH formation occurs extra- as well as intracellularly. 
*OH always causes site-directed cell damage where it 
occurs. 
Generation of oxygen radicals by inflammatory cells is 
known to play an important part in the killing of several 
bacterial and fungal strains. H,O, is used in a thyroid 
peroxidase mediated reaction to produce thyroid hormones 
or it can induce gene expression (e.g. cytoplasmatic gene 
transcription factor) (5,12). Because tumour necrosis factor 
(TNF), hyperthermia, and anti-cancer drugs such as adri- 
amycin produce oxidants that cause tumour cell lysis, ROS 
seem to be meaningful in the natural defence against the 
development of cancer (13). Apart from the natural role 
oxygen radicals play in the host defence system, in inflam- 
matory processes they notably can contribute to the sever- 
ity of various pulmonary diseases. Since oxygen radicals are 
able to induce DNA-strand breaks, which activate pro- 
oncogenes such as K-ras, C-RaF-I and c-fos, oxygen radi- 
cals are also associated with an increased incidence of 
malignancies as proposed in asbestos exposure related 
tumours (14,15). 
Activated leukocytes (both PMN cells and macrophages) 
release highly reactive reduced oxygen species such as 0, - , 
H,O, and others COH, HOCl, NO, and HO,). The local 
concentrations of oxidants formed by PMN cells, which 
occur during normal cellular oxidative phosphorylation, 
can be extremely high: 2 x lo6 PMN cells stimulated 
with 10 - *M f-Met-Leu-Phe produce 10 ~ ‘M 0, - within 
1 min (9). Secretion of toxic oxygen metabolites into the 
extracelluar milieu is known as respiratory burst 
Also, inhalation of inorganic as well as organic particles 
generates oxidant stress via activation of inflammatory 
cells. Asbestos fibres (e.g. crocidolite) have a high redox 
potential through their iron content (up to 28%) forming 
*OH in the Fenton reaction (16). Asbestos fibres and silica 
in addition trigger cytokine (e.g. TNF) release which stimu- 
lates inflammatory cells to produce high amounts of 
oxidants. In rat lungs inhaled crocidolite enhances anti- 
oxidant activity, and alveolar macrophages have been seen 
to undergo lipid peroxidation that can be blocked by 
anti-oxidants (17,18). 
Interestingly, various cellular mediators released by 
stimulated inflammatory cells may further contribute to the 
oxidant load. Inflammatory mediators such as TNF, IL-l, 
IL-6, IL-S, various lipid mediators such as arachidonic acid 
metabolites prostaglandins, leukotrienes (e.g. B4), the phos- 
pholipid platelet-activating factor and others are involved 
in the autocrine or paracrine activation of macrophages, 
neutrophils, fibroblasts, epithelial cells and endothelial 
cells (19-22). Both activated blood monocytes and neu- 
trophils are attracted into the alveolar space by eicosanoid 
and cytokines released from these alveolar macrophages 
and thus enhance oxidant levels in the epithelial lining. 
Arachidonic acid metabolites can initiate oxidant release of 
activated inflammatory cells and enhance anti-oxidant 
enzyme expression in bronchoepithelial cells (23-27). Phos- 
pholipase A, releases arachidonic acid, which is involved 
directly or as a co-factor in the activation of the neutrophil 
respiratory burst (1:28). In contrast, mediators such as 
TNF; lipopolysaccharide (LPS) and IL-l induce in epi- 
thelial cell types expression of anti-oxidants (e.g. MnSOD) 
(26,29-3 1). 
THE PATHOGENESIS OF OXIDANT-RELATED 
INJURY 
The term lung injury incorporates a wide range of phenom- 
ena characterized by widely differing manifestations, 
including, among others, functional alterations in gas 
exchange, excess of lung water, alterations of puhnonary 
haemodynamics, increased vascular permeability and 
histological evidence of structural damage. An impressive 
variety of insults may cause acute and chronic lung injury. 
One group of these insults affects the lung parenchyma 
directly, whereas others affect the lung via systemic 
mechanisms (32). 
Lung injury is clearly marked by measurable changes as 
result of an inflammatory response where circulating PMN 
cells accumulate in the local vasculature and migrate 
through the vessel wall, the interstitium, and the epithelial 
barriers to gain access to the alveolar lumen. 
Hyperoxia leads to a significant increase of intracellular 
O,- formation which may be one of the reasons why 
patients ventilated under hyperoxic conditions more easily 
develop ARDS (33). Recent experiments done in healthy 
vo!unteers exposed to 100% 0, for 12-18 h by a full-face 
mask not only demonstrated that oxygen caused tracheo- 
bronchitis in most of the volunteers but also revealed that 
epithelial cells are not able to protect themselves from free 
radicals by triggering anti-oxidant (SOD and catalase) gene 
expression during this time period (34). Thus, oxidant- 
related cell injuries such as tracheobronchitis or ARDS in 
humans or low survival rates in animal experiments are 
typical consequences (33:35). 
Bleomycin and the herbicide paraquat cause oxidant 
formation as a result of redox cycling which is Fe depen- 
dent (36,37). Because of its high affinity to DNA; bleomycin 
induces site-directed *OH formation which causes crucial 
DNA damage. Certain xenobiotics, activated by intracellu- 
lar reductases and thereby undergoing oxidative redox 
cycling, exert cell damage via intracellular generation of 
O,-. Lung ,injuries caused by paraquat, bleomycin and 
nitrofurantoin are considered a chemical form of oxygen 
toxicity. As a consequence paraquat toxicity, characterized 
by alveolitis, oedema and bleomycin, is used as a model for 
acute lung injury and pulmonary fibrosis (1,38). 
Cigarette smoke, which has been estimated to contain 
1014 oxidants per puff; and ionizing radiation induce 
inflammatory cells to release oxidants, but both may also 
cause cell injury through direct oxidant formation (39,40). 
Ozone, which contains unpaired electrons, degrades to 
highly reactive *OH. 
Oxidants indirectly contribute to pulmonary injury by 
inactivating anti-proteolytic proteins such as a,-antitrypsin 
(a,-AT) and secretory leukoprotease inhibitor (SLPI). ROS 
cause methionine sulphoxide formation at the active site 
and thus inactivate these anti-proteases. High methionine 
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sulphoxide levels in bronchoalveolar lavage (BAL) fluid of 
patients with ARDS and in BAL fluid of cigarette smokers 
indicate that oxidative processes inactivate anti-proteases in 
their airways more frequently than in normal volunteers 
(41). Because a,-AT is the most important anti-protease to 
inactivate neutrophil elastase specifically, part of the 
oxidant-induced injury may also be due to secondary 
proteolytic damage caused by inactivation of a,-AT. 
Malfunction of a,-AT and therefore high activity levels of 
elastases are known to promote the development of lung 
emphysema (41). Like anti-proteolytic agents, anti-oxidants 
such as SOD can also be inactivated by oxidants 
(e.g. H,o,) (~42). 
There is multiple evidence that oxidative events associ- 
ated with acute lung injury may also induce lipid peroxida- 
tion and consequently affect the lung surfactant system 
(43). Disturbance of the surfactant systems leads to 
acceleration of further lung injury (44). 
Anti-oxidants 
PRINCIPLES OF ANTI-OXIDANT DEFENCE 
Normally, in the lung exists an oxygen-rich environment 
sensitively balanced between the toxicity of oxidants and 
protective measures of various intracellular and extra- 
celluar anti-oxidants. Overlapping activities of anti- 
oxidants (e.g glutathione and catalase are both scavenging 
H,O,) indicates tight control of redox balance specifically to 
protect the cells without blocking the physiological role of 
cellular oxidants. To encounter the damaging effect of oxy- 
gen metabolites, the cells in the lung have a sophisticated 
network of anti-oxidant defence mechanisms. If exposed to 
oxidants, pulmonary cells (e.g. bronchoepithelial cells) are 
even able to enhance their anti-oxidant defence. For 
example, in smokers glutathione levels in BAL fluid are 
generally higher than in non-smokers; asbestos fibres cause 
an increase in MnSOD mRNA levels (4548). However, the 
interrelationship between ROS and anti-oxidants in humans 
is very complex, and thus just the basic mechanism should 
be mentioned here [for further reviews see (7,49-51)]. 
Oxidant-scavenging systems can be categorized into the 
following groups: (a) enzyme systems, (b) fat-soluble 
compounds, (c) water-soluble compounds and (d) high 
molecular weight anti-oxidants (49). According to this 
classification, these agents are present in varying degrees in 
the intracellular or extracelluar spaces: (a) SOD, catalase, 
glutathione redox cycle compounds and glutathione 
peroxidase, glutathione reductase, glucose-6-phosphodi- 
hydrogenase; (b) vitamin E, p-carotene, bilirubin; (c) vita- 
min C, uric acid, glucose, cysteine, cystamine, reduced 
glutathione (GSH), taurine; (d) tracheobronchial mucus, 
albumin. SOD, catalase and the compounds of the gluta- 
thione redox cycle are the primary intercellular anti-oxidant 
defence mechanism to cope with ROS. 
The most important H,O,-removing system in human 
cells is the glutathione redox cycle including the glutathione 
peroxidases (GSHPX). GSH is oxidized to GSSG and thus 
removes H,O,. Glutathione reductase regenerates GSH 
Glucose-6-phosphate 
dehydrogenase 
6-Phosphogluconate 
dehydrogenase Ribulose-6- 
F 
r---- phosphate 
NADP+ NADPH 
Glutathione reductase 
GSH GSSG 
2H202 b 2H,O + 0, 
Glutathione peroxidase 
GSH oxidation 
by peroxides, 
thiol transferases 
FIG. 1. Glutathione redox cycle. Reduced glutathione 
(GSH) is oxidized to GSSG and thus removes H,O,. 
Although GSH alone can react with a variety of perox- 
ides, the reaction is more efficiently catalysed by gluta- 
thione peroxidase or thiol transferases. Glutathione 
reductase regenerates GSH from GSSG, with NADPH as 
a source of reducing power (52). 
from GSSG, with NADPH as a source of reducing power 
(Fig. 1) (52). Located in the peroxisomes, catalase catalyses 
like GSH the dismutation of H,O, into water and 0,: 
2H,0,*2H,O + 0, 
Because of their conversion into *OH and into reactive 
radical metal complexes, the conversion of 0, - and H,O, 
into less toxic products is from major importance in living 
cells (53). Therefore, sufficient anti-oxidant augmentation 
therapy can only be expected when these oxidants are 
scavenged or cellular metabolism leading to increased 
production of oxidants is attenuated. 
PHARMACOLOGICAL INTERVENTIONS TO 
ENHANCE CELLULAR ANTI-OXIDANT DEFENCE 
SOD, catalase and GSH in particular, but also a whole 
variety of other substances with direct and indirect anti- 
oxidant capabilities (see previous section), prevent oxida- 
tive cell injury in cell culture as well as in viva in animal 
models and in humans (38,49,5456). However, the effec- 
tiveness of anti-oxidant treatment in viva faces a dilemma: 
the administration of SOD (although available in recom- 
binant form) and catalase is limited by the large molecular 
mass of both proteins. Liposome encapsulation (or conju- 
gations with polyethylene glycol) has been successfully used 
to enhance SOD, catalase and GSH efficiency, but absence 
of phagocytes was required (57,58). Aerosolization of pure 
GSH was characterized by a low half-life (55). Vitamin E 
protects just vitamin-E-deficient animals. Although vitamin 
C can scavenge oxygen species and thus reduce the occur- 
rence of malignancies, it is generally not considered as a 
major anti-oxidant because it has additional pro-oxidant 
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properties (38,49). Another approach would be to stimulate 
cells to produce anti-oxidants. NAC has such a potential, 
because when deacetylated it provides cysteine for cellular 
glutathione synthesis (49;59). Other substances such as 
ambroxol also have direct anti-oxidant properties and like 
NAC a whole variety of indirect anti-oxidant functions. 
Ambroxol is able to reduce oxidant-related cell damage 
through inhibition of phospholipases, stimulation of the 
lung surfactant system (e.g. stimulation of alveolar phos- 
pholipid secretion), inhibition of cytokines such as IL-l and 
TNF, and inhibition of chemotaxis response of neutrophils 
to formyl-methionyl-leucyl-phenylalanine (fMLP) (60-62). 
(a) SH - CH, - CH - COOH 
I 
NH-C-CH, 
II 
0 
2 (R-SH) c H,O, - R-S-S-R+2H,O 
1 (b) 
C&-NH OH 
NH, 
Br 
N-acetylcysteine 
DIRECT ANTI-OXIDANT ACTION OF 
N-ACETYLCYSTEINE 
NAC, which was developed in the 1960s is the N-acetyl 
derivative of the naturally occurring amino acid L-cysteine 
(63). Because of its ability to reduce disulphide bonds it 
is widely used to reduce viscosity and elasticity of mucus 
and is virtually non-toxic (64). The molecular weight is 
163.2 g mall i and the molecular formula is C,H,NO,S. 
The oxidant scavenger function of NAC can easily be 
explained by the chemistry of this molecule. Because of its 
SH group [Fig. 2(a)] NAC has the potential to interact 
directly with oxidants such as H,O, to form H,O, and 0, 
(64,65). In this reaction two NAC molecules are oxidized to 
a disulphide bond [Fig. 2(a)]. The rate constant with 0, - is 
significantly low (64,66). NAC, like many thiols such as 
GSH, is an excellent scavenger of *OH radical (rate 
constant: 1.36 x 10” M- ’ s- ‘). In addition, NAC also 
scavenges HOC1 (64). 
GLUTATHIONE PRECURSOR FUNCTION OF 
N-ACETYLCYSTEINE IN VITRO AND IN 
ANIMAL EXPERIMENTS 
In addition to oxidant scavenger function, there is plenty of 
evidence showing that NAC promotes cellular glutathione 
production, and thus NAC reduced or even prevented 
oxidant mediated damage to cell culture or animals. 
Administration of 2 lop5 M NAC to A549 cells 
(ATCC), a human-derived cell line with epithelial charac- 
teristics, resulted in an approximately ten-fold increase of 
intracellular glutathione levels (65). Because bovine pul- 
monary artery endothelial cells and lung type II epithelial 
cells transported cysteine more efficiently than cystine it 
seems likely that cysteine is the principal substrate for 
cellular glutathione production (67). Cysteine is derived 
from N-deacetylation processes of NAC and/or from the 
reduction of cystine to cysteine (68). Although additional 
mechanisms have been discussed, it seems likely that 
N-deacetylation of NAC represents the key mechanism for 
the cellular glutathione precursor effect (67,69,70). 
Wagner et al. investigated in 12 dogs the preventive effect 
of intravenous NAC against 0, toxicity (71). Concomi- 
FIG. 2. (a)The molecule of N-acetylcysteine (N-acetyl-L- 
cystein) [modified according to (63)]. NAC is the N-acetyl 
derivative of the naturally occurring amino acid 
L-cysteine. Through its SH group it has mucolytic and, 
like glutathione, subsidiary anti-oxidative capabilities. In 
addition, the SH group can be oxidized with oxidants 
such as H,O, to form H,O, and 0, (64,65). In this reac- 
tion two NAC molecules are oxidized to a disulfide bond 
(R=residue). (b) The molecule of ambroxol [tralzs-4-(2- 
amino-3,5-dibromobenzylamino)-cyclohexane hydro- 
chloride]. Ambroxol has a high affinity for lung tissue ’ 
resulting, in approximately 20 times higher concentrations 
in the lung than in plasma after oral or i.v. admin- 
istration (143). It has been used for more than 20 yr for 
its mucolytic capabilities (154). Furthermore, ambroxol 
has been proven to scavenge oxidants directly and reduces 
peroxidative cellular metabolites in in ilitro and animal 
studies (60;133). 
tantly, NAC treatment resulted in a significant decrease of 
pulmonary vascular resistance, and arterial carbon dioxide 
tension, delayed development of abnormal ventilation- 
perfusion relationships and reduced alveolar and interstitial 
oedema (71). In endotoxin-exposed rats NAC treatment 
improved ARDS-like injury by ameliorating structural lung 
damage and reducing lung wet weight and lung albumin 
leakage and it resulted in a reduction of thromboxane B, 
and 6-keto-PGF,, (prostaglandin) in BAL fluid. The 
authors related these results mainly to the GSH precursor 
effect of NAC (72). 
NAC also protects against pulmonary 0, toxicity as well 
as against ischaemic and reperfusion damage. Various 
physiological evaluation measures in dogs ventilated with 
100% 0, for 54 h were improved in the NAC group (71). 
When only given on reperfusion after artificial ischaemia 
in isolated rabbit hearts, NAC had no altering effect on 
cellular glutathione levels. However, when NAC was 
administered prior to coronary ischaemia (60 min), tissue 
GSH was increased by almost 40%, and ischaemia-induced 
decrease of GSH and protein SH, as well as leakage of 
creatine kinase, was limited. Interestingly, mitochondria; 
isolated after ischaemia, maintained their natural oxidative 
phosphorylating capacities (73). 
In addition to this evidence of its anti-oxidant functions, 
NAC has also anti-inflammatory capabilities. Oral admin- 
istration of NAC reduces humoral markers in BAL 
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N-acetylcystine Glutathione Cystine 
---A 
N,N-diacetylcysteine +N-acetyl-L-cyst&e + Cyst&e - Cysteic acid 
//I l Taurine 
Labile disulphide complex with Incorporation into Bile acid 
tissue and plasma proteins protein chains I 
f 
Bile acid 
complex 
FIG. 3. Metabolic pathway of NAC [modified according to (63)]. 
fluid (NAC in healthy individuals) (74). NAC increases 
leukotriene B, (LTB,) secretion, which is usually found in 
low levels in alveolar macrophages of smokers (75). 
Because NAC is acidic in solution, inhalation of this 
substance may be related to coughing. A new approach is 
the development of nacystelyn (NAL), a lysine salt of NAC. 
NAL can easily be administered into the lung by aerosoli- 
zation without causing significant side-effects (76). The 
mucolytic activity of NAL may be more potent than the 
activity of NAC at equimolar concentrations (77). Surpris- 
ingly, NAL seems to have an additional inhibitory effect on 
human neutrophil elastase activity in vitro (76,77). This 
dual function would make this drug particularly useful in 
inflammatory airway diseases in which an overload of 
proteases play a major role in the pathogenesis (e.g. cystic 
fibrosis, a,-AT deficiency) (78,79). Future analyses have to 
show whether NAL can hold its promise also in vivo. 
Moreover, it has to be demonstrated whether NAL has 
inhibitory functions on free radicals and whether it has 
GSH precursor function like NAC. In comparison with 
NAC, NAL revealed similar H,O, scavenger capabilities 
as well as cellular GSH precursor function when 
used in micromolar concentrations, which was recently 
demonstrated in vitro (65). 
PULMONARY METABOLISM OF 
N-ACETYLCYSTEINE 
A schematic representation of the proposed metabolism of 
NAC is given in Fig. 3. After intravenous or oral applica- 
tion NAC is quickly absorbed and undergoes rapid and 
extensive metabolism in gut wall and liver, resulting in a 
bioavailability of about 10% (80,81). Deacetylation of NAC 
arises through metabolic deposition which is catalysed by 
N-deacetylase located in or on the cells. At 1 h after 
administration plasma total NAC is present in a covalently 
protein-bound form. After i.v. administration the terminal 
half-life of total acetylcysteine is 5.6 h (82). At lo-12 h after 
a single dose of NAC only traces could be found (83). After 
i.v. administration, the renal clearance accounts for about 
30% of the total clearance, and approximately 30% is 
secreted in urine during the first 12 h (84). 
As a main condition for anti-oxidant function in the 
lung, concentrations of NAC or its metabolites in the lung 
interstitium, bronchoepithelial cells and/or in the epithelial 
lining have to be sufficiently elevated (micromolar levels). 
In patients (n= 10; among these n= 5 underwent pneumon- 
ectomy or lobectomy) with respiratory disorders total 
radioactivity in plasma, lung tissue and bronchial secretions 
was determined after oral demonstration of 100 mg 
[35S]NAC. Lung tissue radioactivity (after 5 h) was compar- 
able with plasma levels (85). Just small amounts of radio- 
activity were found in the bronchial sections (85). After 
administration of 200 mg t.i.d. for 2 weeks to healthy 
volunteers neither NAC nor its metabolites were detected in 
the BAL fluid (86). Also 600-1800 mg NAC [given daily by 
mouth to patients with chronic obstructive pulmonary 
disease (COPD)] failed to increase levels of NAC, cysteine 
and glutathione in BAL fluid, ELF and lung tissue (87). It 
can be concluded from these findings, and in contrast to the 
increase of plasma levels, that after oral or i.v. admin- 
istration NAC can only be expected on the epithelial 
lining or in bronchoepithelial wall in traces at best. How- 
ever, NAC frequently has to be used to balance the 
oxidant-anti-oxidant system in human pulmonary diseases. 
ANTI-OXIDANT PROPERTIES OF 
N-ACETYLCYSTEINE IN HUMANS 
To investigate anti-oxidant properties of NAC, in most 
studies doses between 200 mg and 600 mg daily (oral 
administration), and up to 150 mg kg - i (i.v. as a loading 
dose) in patients with ARDS, were administered (75,87-90). 
Overall, it is difficult to relate successful treatment 
exclusively to the anti-oxidant effect of NAC since it also 
has mucolytic properties. Most studies indicate that 
the therapeutic potential of NAC in the treatment of 
inflammatory disorders of the human lung is associated 
with its direct scavenger effect and/or its ability to increase 
cysteine, the main cellular glutathione precursor. Some 
authors, however, failed either to increase anti-oxidant 
function in human lung or to reduce the activation state of 
inflammatory cells by oral NAC administration (91-93). 
NAC in Healthy Individuals 
The effect of NAC in enhancing anti-oxidant defence in the 
lungs’ of healthy volunteers is marginal. In 11 normal, 
non-smoking volunteers (aged 24-37 years) O,- as well as 
H,O, release of freshly isolated neutrophils from whole 
blood remained unchanged after oral administration of 
600 mg NAC daily for 5 days (93). In normal individuals 
i.v. administration of various doses of NAC had no signifi- 
cant effect on glutathione concentrations in BAL 
fluid. Compared with baseline values (0.79 & 0.17 ,uM), 
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administration of 600 mg NAC (0.92 f 0.33~~) 1.8 g 
NAC (1~4~tO.4~~) and 4.8 g NAC (1.33 &0.46& did 
not significantly increase total glutathione levels (3 h after 
iv. application) (94). Meyer et al. hypothesized that lack of 
glutathione increase in BAL fluid after NAC administration 
might be due to various reasons. First, NAC may support 
glutathione synthesis only in situations of increased 
demand on the cellular glutathione pool following oxidative 
stress (e.g. after paracetamol intoxication or in patients 
suffering from IPF) (94). Second, the rapid clearance of 
most of the NAC and its products could limit its effect and, 
third, increasing glutathione levels in BAL fluid might 
suppress local glutathione synthesis by feed-back inhibition 
(94,95). 
In addition to the failure of NAC to increase glutathione 
or cysteine levels in BAL fluid (or ELF) in healthy individ- 
uals, NAC (200 mg t.i.d.) significantly (P<O.OOl) reduced 
various inflammatory parameters in BAL fluid in 11 
healthy smokers: lactoferrin, eosinophil cationic protein, 
anti-chymotrypsin and chemotactic activity of neutrophils. 
In serum-plasma the concentrations of myeloperoxidase 
and elastase were also reduced by NAC (74). 
Kleinfeld et al. (92) found in six healthy normolipidaemic 
adult volunteers that NAC (2 x 600 mg for 4 weeks, fol- 
lowed by 2 x 1200 mg for 2 weeks) had no effect on the 
susceptibility of LDL (low-density lipoprotein) oxidiza- 
bility. Unexpectedly and in contrast to other investigations, 
NAC administration even resulted in reduction of plasma 
GSH and increase of GSSG (92). 
NAC in Respiratory Disorders 
Among others, patients with ARDS, IPF or COPD have 
been the primary targets for clinical studies to evaluate the 
efficacy of NAC in anti-oxidant therapy. 
ARDS is of multifactorial origin, and at a certain stage of 
its development strong oxidative stress through massive 
PMN activation becomes a predominant condition. Con- 
comitant glutathione-mediated anti-oxidant protection is 
low in the alveolar fluid of these patients (96). Mechanical 
ventilation with high concentrations of oxygen further 
enforces the release of reactive oxygen metabolites (33,97). 
To balance the oxidant-anti-oxidant system, patients with 
ARDS (n=30) were treated i.v. with high doses of NAC. 
After an initial dose of 150 mg kg ~ ’ followed by 
24 mg kg - ’ every 4 h, initially low plasma and red cell 
glutathione levels increases. In addition, improvements of 
chest radiograph oedema, vascular resistance, oxygen 
delivery and oxygen consumption were achieved (98). Spies 
et al. (89) confirmed this result in a placebo-controlled 
study: in the NAC-responder group (50% of all patients) 
65% of patients with a septic shock who initially received 
150 mg kg - i in 15 min of NAC, followed by 125 mg kg - ’ 
h- ‘, had a better survival rate (89). With i.v. NAC 
(40 mg kg- i day- ‘) Suter and coworkers improved sys- 
temic oxygenation and reduced the need for ventilatory 
support in patients presenting with mild-to-moderate acute 
lung injury. However, the development of ARDS and 
patients’ survival (mortality) was not significantly reduced 
by this therapy: the 1 month mortality rate was 22% for 
the NAC group (1z=32) and 35% for the placebo group 
(n=29) (99). 
IPF is characterized by alveolar inflammation, exagger- 
ated release of reactive oxygen metabolites and subnormal 
concentrations of glutathione in the ELF (100,101). Direct 
glutathione administration via the aerosol route but also 
NAC given iv. or by mouth increased significantly BAL 
Auid (or ELF) glutathione levels (55;90;94). In 17 non- 
smoking patients with biopsy-proven IPF receiving 
3 x 600 mg NAC day ~ ’ for 5 days BAL fiuid total gluta- 
thione levels increased significantly (P<O.O06) from 
0.99 * 0.12 to 1.54 + 0.24)~~~ (90). Also, i.v. administration 
of different NAC concentrations to patients with IPF 
increased total glutathione in BAL fluid significantly 
(P<O.O3). BAL fluid total glutathione levels rose from 
0.99 & 0.25~~ to 1.79 * 0.37~~ (after 1.8 g NAG). A fur- 
ther increase of BAL fluid total glutathione levels after 
higher doses (4.8 g NAC) was not observed (1.47 It 0.34 pM) 
(94). High concentrations of total glutathione were almost 
entirely due to GSH (about 94-97%) (94). However, these 
results do not mandate clinical efficacy of NAC treatment 
because just biochemical alterations have been demon- 
strated in these studies. This has still to be demonstrated,in 
long-term studies. 
Also, in COPD patients NAC treatment was tested to 
improve anti-oxidant levels although this disease, with the 
possible exception of severe cases, is not characterized by 
glutathione deficiency. NAC has been used for over two 
decades in the treatment of COPD and some studies 
demonstrated beneficial effect, but others have not (102- 
104). Oral administration of NAC to patients with COPD 
(two groups, one received 600 mg once daily, the second 
600 mg thrice daily) resulted in a significant (PcO.05) 
increase of NAC in blood 1.5 h after the drug was given 
(after 5 days treatment). Sustained elevation of plasma 
glutathione and cysteine levels was only observed in the 
group treated with the higher dosage. In contrast, neither 
GSH nor cysteine levels rose in BAL fluid, ELF or lung 
tissue (87). 
These results, a negative effect in healthy volunteers or 
patients with COPD (normal glutathione levels in BAL 
fluid) and beneficial effect of NAC treatment in patients 
with IPF or ARDS (low glutathione levels in BAL fluid, 
high oxidant load), support the hypothesis of negative 
feedback inhibition (see previous section) (95). In agree- 
ment with this concept, patients with a hereditary deficiency 
of glucose -6-phosphodehydrogenase, who are more sensi- 
tive to oxidative stress, were also successfully treated with 
NAC. In these patients NAC treatment augmented not only 
glucose-6-phosphodehydrogenase activity but also reduced 
effective lipid peroxidation and made these erythrocytes 
more resistant to incubation with acetylphenylhydracine, 
an agent causing oxidative stress (105,106). 
NAC is virtually non-toxic. When used in humans NAC 
rarely causes anaphylaxis, tachycardia or hypotension 
(107,108). Only very high concentrations in in vivo and 
in vitro experiments revealed that > 10 - 3 M reduces chemo- 
taxis and >O.l M increases cytotoxicity of PMN cells (107). 
Because of the low bioavailability, it is not feasible to 
achieve these concentrations in humans (84,109). 
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N-ACETYLCYSTEINE AS AN ANTIDOTE 
From 5% to 10% of paracetamol is metabolized to 
N-acetylbenzochionimine. This metabolite reacts with 
thiols and thus can be detoxified. However, toxic amounts 
of paracetamol (intake about 2 6 g) overwhelm cellular 
glutathione supplies, eventually causing liver necrosis (110). 
Because approximately 70% of NAC is metabolized in the 
liver, NAC has been proven to be a useful antidote in 
paracetamol intoxication, which conjugates with reduced 
glutathione (63,111). In the liver, such antidote action is 
related to NAC as an effective precursor to supply intrac- 
ellular cysteine, which is intracellularly transformed into 
GSH. Thus, the NAC-mediated GSH increase not only 
conjugates paracetamol to less toxic metabolites but it also 
makes GSH available for anti-oxidant defence purposes 
intracellularly as well as extracelluarly (63). 
NAC given orally also has a cardioprotective effect 
in patients treated with doxorubicin, it reduces 
cyclophosphamide-induced haemorrhagic cystitis and it 
attenuates bleomycin-related changes in lung function 
(112,113). 
Patients successfully treated for lung cancer remain at 
high risk to develop a secondary primary tumour. In 
Euroscan [the European Chemoprevention Study under the 
auspices of the European Organization for Research and 
Treatment of Cancer (EORTC)] patients after successful 
treatment of lung or head and neck cancer are randomized 
as follows: NAC (600 mg day - ’ for 2 yr), retinol palmitate,’ 
the combination of both or no drugs. To date, more than 
2600 patients have been included. Only 8% suffered from 
side-effects (mild gastrointestinal symptoms) (114,115). 
With NAC, the authors hope to reduce the risk of second 
tumours. Reduction of the development of second tumours 
is based on the knowledge that thiols inhibit the mutagenic 
response to potent carcinogens such as benzo[a]pyrene, 
2-aminofluorene and aflatoxin p,, reduces oxidant- 
mediated DNA damage and stimulates DNA repair mecha- 
nisms (115). 
Ambroxol 
PHYSIOLOGICAL EFFECTS OF AMBROXOL 
Ambroxol [tvans-4-(2)amino-3,5-dibromobenzylamino)- 
cyclohexane hydrochloride; Fig. 2(b)] stimulates synthesis 
and secretion of surfactant by type II pneumocytes 
(116,117) and inhibits sodium absorption by airway epi- 
thelial cells (118). It can also accelerate the maturation of 
the foetal lungs by increasing the lecithin: sphingomyelin 
ratio (119). Ambroxol is used as a mucolytic drug and lower 
sputum viscosity by normalizing secretions from bronchial 
glands. In this context, ambroxol, has been widely tested to 
prevent chronic bronchitis exacerbations, to improve the 
clearance mechanism of the epithelial surface of the air- 
ways, to decrease bronchial hyperreactivity and even to 
promote secretion mechanisms in patients with otitis media 
and to reduce the occurrence of neonatal respiratory 
distress syndrome by induction of foetal lung maturation 
(120-125). 
ANTI-OXIDANT ACTIVITY OF AMBROXOL IN 
VITRO 
At concentrations of 10K6-10- ’ M and 2.5-l x lo- 5 M 
respectively ambroxol revealed a capacity to inhibit *OH- 
and HOCl-mediated reactions (126). As a scavenger of 
these two ROS ambroxol was almost equipotent to di- 
methylsulphoxide and methionine (126). The inhibition of 
0, - -dependent auto-oxidant of pyrogallol and decom- 
position of H,O, by ambroxol was low over a large 
concentration range. The capacity of ambroxol to scavenge 
HOC1 and *OH can explain the above-mentioned inhibitory 
effect of this drug on chloramine-T- and cigarette-smoke- 
induced decrease of serum elastase inhibitory capacity 
(127,128). Both of these factors inactivate a,-AT via 
generation of HOC1 and *OH. 
Ambroxol was shown to inhibit lipid peroxidation in 
liver homogenates exposed to the Fe2+-ascorbate system. 
At a concentration of 2-l x 10 ~ 4 M it decreased two-fold 
the conversion of liver lipids into thiobarbituric acid 
reactive substances (129). In another study 2.5 x 10 -’ M 
ambroxol protected linoleic acid from peroxidative damage 
induced by the H20,Fe2+ -EDTA system in vitro (126). At 
very high concentrations (millimolar range), which, how- 
ever, are irrelevant for therapeutic use in humans, ambroxol 
completely inhibited *OH-induced peroxidation of linoleic 
acid as expressed by malondialdehyde (MDA) generation. 
The authors speculate that two mechanisms are responsible 
for these effects, first direct *OH scavenging effect of 
ambroxol and second the ability of the two nitrogen atoms 
of the drug molecule to chelate iron (130). 
AMBROXOL AS LIPID ANTI-OXIDANT IN 
ANIMAL STUDIES 
Ambroxol was demonstrated to reveal protective efficacy 
for lung and heart lipids that was comparable with and even 
higher than those of NAC and methionine (131-133). 
Ambroxol injected once per day (70 mg kg - i) for three 
consecutive days decreased the LPS (17 mg kg-r) induced 
lipid peroxidation in murine organs (133). The lung and 
heart levels of conjugated dienes (CDs) in animals pre- 
treated with ambroxol were 3.3 and 1.7 times lower than 
those observed in the control group which received buffer 
and subsequently LPS (132). NAC did not inhibit the 
LPS-induced (IL-l- and TNF-dependent) hypothermic 
reaction in mice, while ambroxol inhibited the loss of body 
temperature from 4.1 & 1.3 to 2.2 f 0.9”C (132,133). These 
protective effects of ambroxol may result from its ability to 
scavenge *OH and the inhibition of IL-1 and TNF release 
from LPS-activated monocytes (126,134). 
In another study mice were injected i.p. with equimolar 
doses (1.7 x 10 - 4 M kg ~ ‘) of ambroxol, NAC, methionine 
or solvent once per day for three consecutive days. Lipid 
peroxidation was induced in organ homogenates by means 
of heat (50°C) or 10 - 5 M H,O, (131). Ambroxol inhibited 
the thermal generation of CDs (one of the first lipid 
peroxidation products) in lung homogenates. This inhibi- 
tion (59.9 * 33.1%) was similar to that with NAC 
(61.1 & 26.1%) but was l.Cfold higher than that observed 
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TABLE 3. Effects of ambroxol in vitro and ex vivo 
Action Concentration or dose Conditions 
(1) Direct anti-oxidant activity 
l -OH scavenger 
e HOC1 scavenger 
(2) Lipid anti-oxidant: inhibition of lipid 
peroxidation induced by 
* *OH 
l H A  
* temperature, 50°C 
* endotoxin (LPS) 
l doxorubicin 
(3) Inhibition of human phagocytes 
l chemotaxis 
* spontaneous migration 
0 chemiluminescence 
e IL-l and TNF release 
0 modulation of intracellular Cat 
1op3-10-‘M 
2.5-1.5 X 10-5M 
2.5 x 1O-4-5x 1op3M 
i.p. 3 x 70mgkgg’ 
i.p. 3 x 70mgkgg’ 
i.p. 3 x 70mgkg-’ 
i.v. 1 x 70mgkg-i 
1op5M 
9.6-3.8 X 10-5M 
1.9 X 10-4M 
2.4 x 1O-5-2.4x 10-4~ 
10-4M 
In vitro 
In vitro 
In vitro 
Ex vivo 
Ex vivo 
In vitro 
In vivo 
In vitro 
In vitro 
In vitro 
In vitro 
In vitro 
The results obtained in the millimolar range are interesting from a scientific point of view but 
irrelevant in humans; because of low bioavailability it is not feasible to achieve concentrations of this 
order of magnitude by therapeutic administration. 
for methionine. In addition, H,O,-induced generation of 
CDs in lungs from ambroxol-treated mice was 3.1-fold 
lower than that found in lung homogenates from the 
control group. In contrast, NAC and methionine failed to 
protect the lung lipids from H,O,-provoked peroxidative 
damage (131). This finding indicates that injection of 
ambroxol increases the lung anti-oxidant defence against 
heat and H,O,. 
When applied first, a single intravenous injection of 
ambroxol (70 mg kg ~ ‘) completely protected heart lipids 
from peroxidative damage induced by doxorubicin in mice 
(135). The heart content of CD and MDA in the animals 
that received ambroxol and doxorubicin was about three- 
fold lower than that found in the doxorubicin-treated mice. 
Ambroxol revealed also a protective action against other 
anti-cancer drugs and xenobiotics (e.g. bleomycin, 
paraquat) that are known to induce oxidative stress in 
tissues (136,137). 
ANTI-INFLAMMATORY PROPERTIES OF 
AMBROXOL 
The inhibition of phospholipases A present in lung and 
alveolar lysosomes is an important mechanism by which 
ambroxol enhances the content of surfactant in the 
bronchoalveolar lining fluid (61). Ambroxol decreased 
the total activity of phospholipases A in rabbit alveolar 
macrophages, peritoneal cells and PMN cells (138;139). 
Furthermore, ambroxol at physiological concentrations 
(micromolar range) inhibited the spontaneous migration 
and chemotactic response of human PMN cells to purulent 
sputum, zymosan-activated serum and fMLP (60,140). 
Human monocytes cultured in medium containing 
ambroxol released less IL-l and TNF after stimulation with 
LPS (134). The significant inhibition of biosynthesis of 
these two pro-inflammatory-pro-oxidant cytokines was 
observed just at an ambroxol concentration of 10,~~. 
Ambroxol (24-9.6 x 10 ~ 5 M) attenuated the spontaneous 
and zymosan-induced lucigenin-dependent chemilumines- 
cence of human PMN cells (6). This inhibition of phagocyte 
chemiluminescence may be a result of phospholipase 
inhibition with subsequent suppression of the respiratory 
burst and a direct scavenging effect of ROS. However, 
pre-incubation of human PMN cells and monocytes with 
ambroxol had no influence on phagocytosis and killing of 
Candida albicans (141). In dogs exposed to ozone aerol- 
solized ambroxol inhibited the development of airway 
hyperresponsiveness to acetylcholine but did not decrease 
the PMN cell influx into the lower airways (142). 
Table 3 summarizes the main effects of ambroxol indicat- 
ing anti-oxidant and anti-inflammatory properties. Most of 
these effects came from in vitro or animal experiments using 
concentrations which are feasible to achieve (micromolar 
range) in human lung tissue (143). 
ANTI-OXIDANT FUNCTION OF AMBROXOL IN 
HUMANS 
Despite substantial evidence of the apparent anti-oxidative 
effect of ambroxol in vitro or in animals, only few studies in 
humans have been published. One describes that additional 
administration of ambroxol in cancer patients prevented 
deterioration of the lung function related to anti-cancer 
treatment with bleomycin and nitrosourea (144). Red 
blood cells of pre-term infants of mothers pre-treated 
i.v. with ambroxol revealed a decreased content of lipid 
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peroxidation products and enhanced anti-oxidant defence 
(145). While NAC cannot be detected in BAL fluid after i.v. 
or oral administration, ambroxol has a very high affinity for 
lung tissue, resulting in approximately 20 times higher levels 
in the lung than in serum. Thus, micromolar concentrations 
can be achieved in lung tissue after the administration of 1 g 
ambroxol (143). In a large double-blind multicentre trial 
252 patients were enrolled receiving 1 g day - r of ambroxol 
iv. for six consecutive days before upper abdominal sur- 
gery. In this trial Feigz et al. demonstrated that there was a 
significant reduction in atelectasis between the ambroxol 
and the placebo groups (p<O.O5; ambroxol 10.6%, placebo 
23.9%) (146). Furthermore, high doses of ambroxol (1 g 
day - ‘) may prevent postoperative ARDS and broncho- 
pulmonary complications after chest surgery (147). ‘1.~. 
administered ambroxol (10 mg kg- ‘, twice daily for 1 
week) was shown to increase survival of 28 neonates (birth 
weight 12000 g) with idiopathic respiratory distress syn- 
drome which is related to its stimulatory effect on cellular 
surfactant production (148). To understand the anti- 
inflammatory effect of surfactant, it is important to know 
that it contains anti-oxidants such as SOD and catalase and 
that it inhibits cytokine release and thus reduces the respir- 
atory burst of inflammatory cells (149-15 1). By stimulating 
surfactant production in the airways, ambroxol may 
indirectly reduce the oxidant burden in the lung. Bronchial 
reactivity to metacholine was reduced two-fold (compari- 
son vs. placebo) when ambroxol was administered orally to 
asthmatic patients (90 mg day- *, for a 14 day period) 
(122). To summarize, numerous parameters (physiological 
and biochemical) for both substances indicate the potential 
usefulness of this therapeutic approach. 
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